4D Molecular Therapeutics Inc (FDMT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2020 | 09-2020 | 06-2020 | 03-2020 | 12-2019 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 276,726 | 0 | 0 | 0 | 49,652 |
| Receivables | 1,486 | 0 | 0 | 0 | 978 |
| Other current assets | 0 | 0 | 0 | 0 | 1,878 |
| TOTAL | $282,656 | $0 | $0 | $0 | $52,508 |
| Non-Current Assets | |||||
| PPE Net | 5,073 | N/A | N/A | N/A | 7,674 |
| Other Non-Current Assets | 602 | 0 | 0 | 0 | 677 |
| TOTAL | $5,675 | $N/A | $N/A | $N/A | $8,351 |
| Total Assets | $288,331 | $0 | $0 | $0 | $58,234 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 1,787 | 0 | 0 | 0 | 1,744 |
| Accrued Expenses | 8,371 | 0 | 0 | 0 | 5,347 |
| Other current liabilities | N/A | 0 | 0 | 0 | 5,864 |
| TOTAL | $16,744 | $0 | $0 | $0 | $12,955 |
| Non-Current Liabilities | |||||
| Deferred Revenues | 6,586 | N/A | N/A | N/A | N/A |
| Other Non-Current Liabilities | 1,974 | 0 | 0 | 0 | 104,646 |
| TOTAL | $15,200 | $N/A | $N/A | $N/A | $118,249 |
| Total Liabilities | $31,944 | $0 | $0 | $0 | $131,204 |
| Shareholders' Equity | |||||
| Common Shares | 3 | 0 | 0 | 0 | 1 |
| Retained earnings | -135,679 | 0 | 0 | 0 | -79,025 |
| TOTAL | $256,387 | $0 | $0 | $0 | $-72,970 |
| Total Liabilities And Equity | $288,331 | $0 | $0 | $0 | $58,234 |